openPR Logo
Press release

Hypoparathyroidism Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Ascendis Pharma, EnteraBio, Bridgebio, Calcil ytix Therapeutics, Ascendis Pharma, Shire, Chugai Pharmaceutical

06-01-2023 01:44 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Hypoparathyroidism Market is Predicted to Exhibit Remarkable

DelveInsight's "Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Hypoparathyroidism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypoparathyroidism Market Forecast
https://www.delveinsight.com/report-store/hypoparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Hypoparathyroidism Market Report:
• The Hypoparathyroidism market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• When one or more of the parathyroid glands are underactive, hypoparathyroidism results. Approximately 70,000 people have hypoparathyroidism, according to NORD. It can have an impact on people of any age
• Hypoparathyroidism was forecast to affect 22,000 people in Japan overall in 2021, and that number is projected to rise by 2032
• In Japan, the age ranges 55 to 64 and 65 and beyond in 2019 had the greatest incidence rates. While the age groups under 18 are thought to have the fewest instances, accounting for 2.17% of all age groups
• Key Hypoparathyroidism Companies: Ascendis Pharma, EnteraBio, Bridgebio, Calcil ytix Therapeutics, Ascendis Pharma, Shire, Chugai Pharmaceutical, Amolyt Pharma, Takeda, Visen Pharmaceuticals, John P. Bilezikian, and others
• Key Hypoparathyroidism Therapies: TransCon PTH, EB612, Encaleret, NATPARA/NATPAR, Palopegteriparatide (TransCon PTH), NPSP558, PCO371, AZP-3601, rhPTH(1-84), TransCon PTH, open-label PTH(1-84), and others
• The Hypoparathyroidism epidemiology based on gender analyzed that Hypoparathyroidism affects females more than males
• The Hypoparathyroidism market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoparathyroidism pipeline products will significantly revolutionize the Hypoparathyroidism market dynamics.

Hypoparathyroidism Overview
A lack of parathyroid hormone (PTH) secretion or activity causes hypocalcemia and hyperphosphatemia, which are symptoms of hypoparathyroidism. As part of a multigendular autoimmune condition or as a complicated congenital defect, such as in the autosomal dominant DiGeorge or hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromes, hypoparathyroidism can manifest.

Get a Free sample for the Hypoparathyroidism Market Report
https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hypoparathyroidism Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hypoparathyroidism Epidemiology Segmentation:
The Hypoparathyroidism market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Hypoparathyroidism
• Prevalent Cases of Hypoparathyroidism by severity
• Gender-specific Prevalence of Hypoparathyroidism
• Diagnosed Cases of Episodic and Chronic Hypoparathyroidism

Download the report to understand which factors are driving Hypoparathyroidism epidemiology trends @ Hypoparathyroidism Epidemiology Forecast
https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hypoparathyroidism Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypoparathyroidism market or expected to get launched during the study period. The analysis covers Hypoparathyroidism market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypoparathyroidism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypoparathyroidism Therapies and Key Companies
• TransCon PTH: Ascendis Pharma
• EB612: EnteraBio
• Encaleret: Bridgebio/Calcil ytix Therapeutics
• NATPARA/NATPAR: Entera Bio Ltd.
• Palopegteriparatide (TransCon PTH): Ascendis Pharma
• NPSP558: Shire
• PCO371: Chugai Pharmaceutical
• AZP-3601: Amolyt Pharma
• rhPTH(1-84): Takeda
• TransCon PTH: Visen Pharmaceuticals
• open-label PTH(1-84): John P. Bilezikian

Discover more about therapies set to grab major Hypoparathyroidism market share @ Hypoparathyroidism Treatment Market
https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hypoparathyroidism Market Drivers
• Based on the route of administration, the parenteral method will remain the fastest-growing segment compared to oral methods
• Extensive cancer radiation treatment on the neck or face and new technology advancements for the treatment of hypoparathyroidism is set to further enhance the overall development of the hypoparathyroidism treatment market

Hypoparathyroidism Market Barriers
• In terms of drug class, calcium supplements might remain the most preferred in the coming future, with around 38% market share. PTH will also showcase a substantial growth rate
• Sales of hypoparathyroidism treatment drugs through retail pharmacies will generate maximum revenue, followed by hospital pharmacies.

Scope of the Hypoparathyroidism Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hypoparathyroidism Companies: Ascendis Pharma, EnteraBio, Bridgebio, Calcil ytix Therapeutics, Ascendis Pharma, Shire, Chugai Pharmaceutical, Amolyt Pharma, Takeda, Visen Pharmaceuticals, John P. Bilezikian, and others
• Key Hypoparathyroidism Therapies: TransCon PTH, EB612, Encaleret, NATPARA/NATPAR, Palopegteriparatide (TransCon PTH), NPSP558, PCO371, AZP-3601, rhPTH(1-84), TransCon PTH, open-label PTH(1-84), and others
• Hypoparathyroidism Therapeutic Assessment: Hypoparathyroidism current marketed and Hypoparathyroidism emerging therapies
• Hypoparathyroidism Market Dynamics: Hypoparathyroidism market drivers and Hypoparathyroidism market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hypoparathyroidism Unmet Needs, KOL's views, Analyst's views, Hypoparathyroidism Market Access and Reimbursement

To know more about Hypoparathyroidism companies working in the treatment market, visit @ Hypoparathyroidism Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Hypoparathyroidism Market Report Introduction
2. Executive Summary for Hypoparathyroidism
3. SWOT analysis of Hypoparathyroidism
4. Hypoparathyroidism Patient Share (%) Overview at a Glance
5. Hypoparathyroidism Market Overview at a Glance
6. Hypoparathyroidism Disease Background and Overview
7. Hypoparathyroidism Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypoparathyroidism
9. Hypoparathyroidism Current Treatment and Medical Practices
10. Hypoparathyroidism Unmet Needs
11. Hypoparathyroidism Emerging Therapies
12. Hypoparathyroidism Market Outlook
13. Country-Wise Hypoparathyroidism Market Analysis (2019-2032)
14. Hypoparathyroidism Market Access and Reimbursement of Therapies
15. Hypoparathyroidism Market Drivers
16. Hypoparathyroidism Market Barriers
17. Hypoparathyroidism Appendix
18. Hypoparathyroidism Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Hypoparathyroidism Pipeline https://www.delveinsight.com/report-store/hypoparathyroidism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Hypoparathyroidism Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hypoparathyroidism market. A detailed picture of the Hypoparathyroidism pipeline landscape is provided, which includes the disease overview and Hypoparathyroidism treatment guidelines.
Hypoparathyroidism Epidemiology https://www.delveinsight.com/report-store/hypoparathyroidism-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hypoparathyroidism Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Hypoparathyroidism epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hypoparathyroidism Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Ascendis Pharma, EnteraBio, Bridgebio, Calcil ytix Therapeutics, Ascendis Pharma, Shire, Chugai Pharmaceutical here

News-ID: 3074844 • Views:

More Releases from DelveInsight Business Research

Dyspepsia Pipeline Report, 2024 Updates : In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Astellas Pharma Inc, Forest Laboratories, EMS, Dong-A ST Co., Ltd., Xian-Janssen Pharmaceutic
Dyspepsia Pipeline Report, 2024 Updates : In-depth Analysis into the Clinical Tr …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dyspepsia pipeline constitutes 2+ key companies continuously working towards developing 2+ Dyspepsia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Dyspepsia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyspepsia Market. The Dyspepsia Pipeline report embraces in-depth
Acute Respiratory Distress Syndrome Pipeline Assessment | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Mesoblast, Sage Therapeutics, Evgen Pharma, Dimerix Bioscience, Vanda Pharma
Acute Respiratory Distress Syndrome Pipeline Assessment | In-depth Insights into …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Respiratory Distress Syndrome pipeline constitutes 50+ key companies continuously working towards developing 50+ Acute Respiratory Distress Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Acute Respiratory Distress Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across
Psoriatic Arthritis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | ACELYRIN Inc., Sun Pharmaceutical Industries Limited, UCB Pharma, Ventyx Bioscience
Psoriatic Arthritis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Psoriatic Arthritis pipeline constitutes 20+ key companies continuously working towards developing 25+ Psoriatic Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Psoriatic Arthritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriatic Arthritis Market. The Psoriatic
Helicobacter Pylori Infections Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Phathom Pharmaceuticals, Inc., HK inno.N Corporation, Elpen Pharmaceutic
Helicobacter Pylori Infections Pipeline Drugs Analysis Report, 2024 Updates: FDA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Helicobacter Pylori Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Helicobacter Pylori Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Helicobacter Pylori Infections Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Helicobacter Pylori

All 5 Releases


More Releases for Hypoparathyroidism

Hypoparathyroidism Treatment Market Size 2022, Upcoming Demand, Regional Outlook …
Global Hypoparathyroidism Treatment Market to reach USD $billion by 2027.Global Hypoparathyroidism Treatment Market is valued at approximately USD $billion in 2020 and is anticipated to grow with a healthy growth rate of more than % over the forecast period 2021-2027. Hypoparathyroidism Treatment is a treatment in which a low level of parathyroid hormone is produced by hypoparathyroidism. Parathyroid hormone maintains and regulates the balance between calcium and phosphorus. Increasing number of
Hypoparathyroidism Treatment Market Size, Share, Trends, Analysis and Forecast 2 …
The Global Hypoparathyroidism Treatment Market is poised to register a CAGR of over 8% during the forecast period 2020 to 2027. Hypoparathyroidism occurs when the parathyroid glands does not produce enough hormone. Hyperparathyroidism can be caused by a number of factors, including injury or removal of the parathyroid glands, DiGeorge syndrome, an autoimmune disease, cancer radiation treatment, and low magnesium levels. The main function of parathyroid hormone is to regulate blood
New Drug Development and Government Support to Root Out Hypoparathyroidism
The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately 8% through 2026. As per a recent in-depth analysis by Future Market Insights (FMI), the valuation of global hypoparathyroidism treatment market is expected to stand at US$ 663.7 Million in 2019. Although the growth rate is expected to showcase similar trends, the
Global Hypoparathyroidism Global Clinical Trials Market Size, Status and Forecas …
This report studies the global Hypoparathyroidism Global Clinical Trials market, analyzes and researches the Hypoparathyroidism Global Clinical Trials development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Shire Eli Lilly Takeda Aegerion ... Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Get Free PDF for more Professional and Technical insights @ https://www.qyresearchreports.com/sample/sample.php?rep_id=1040462&type=S Market segment by Type, Hypoparathyroidism Global Clinical Trials can
Hypoparathyroidism-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Hypoparathyroidism-Pipeline Review H2 2017” this report provides an overview of the Non-Hodgkin Lymphoma-Pipeline landscape.  Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism-Pipeline Review, H2 2017, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape. Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of
Research Delivers Insight into the Global Outlook for Hypoparathyroidism Treatme …
Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism occurs when the